Enteric coating aureomycin premix

A technology of enteric coating and chlortetracycline, which is applied in the direction of active ingredients of tetracycline, medical preparations of non-active ingredients, digestive system, etc., can solve the problem of discounting the therapeutic effect of intestinal diseases, low bioavailability of chlortetracycline, unfavorable Disease recovery and other problems, to achieve the effect of small particles, good application prospects, and favorable dissolution

Inactive Publication Date: 2018-03-20
江苏昕宇药业有限公司
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] The existing chlortetracycline premix is ​​dissolved in the gastric juice, so that a part of the chlortetracycline is absorbed by the stomach before reaching the intestinal tract, which

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] An enteric-coated aureomycin premix comprises drug-loaded pellets and a coating arranged on the outside of the drug-loaded pellets, and the drug-loaded pellets comprise the following components by weight: 25 parts of aureomycin hydrochloride , 18 parts of low-substituted hydroxypropyl cellulose, 7 parts of povidone K30, 1.8 parts of sucrose, the coating comprises the following components in parts by weight: 22 parts of polyacrylic resin II, 5 parts of plasticizer and 2 parts of talcum powder .

Embodiment 2

[0015] An enteric-coated aureomycin premix is ​​characterized in that: it comprises drug-loaded pellets and a coating arranged on the outside of the drug-loaded pellets, and the drug-loaded pellets comprise the following components by weight: gold hydrochloride 27 parts of mycin, 20 parts of low-substituted hydroxypropyl cellulose, 9 parts of povidone K30, 2.5 parts of lactose, and the coating contains the following components by weight: 20 parts of polyacrylic resin II, 3.9 parts of plasticizer and 3 parts of talcum powder.

[0016] The enteric-coated aureomycin premix includes drug-loaded pellets and coatings arranged outside the drug-loaded pellets, wherein the drug-loaded pellets contain aureomycin hydrochloride, low-substituted hydroxypropyl cellulose, poly Vitamin K30, and sweetener, the coating contains: polyacrylic acid resin Ⅱ, plasticizer and talcum powder, polyacrylic acid resin Ⅱ is insoluble in gastric juice and only soluble in intestinal juice, effectively protec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an enteric coating aureomycin premix, which comprises drug-loading pellets and a coating which is arranged outside the drug-loading pellets. The drug-loading pellets contain the following ingredients (by weight): 20-30 parts of chlortetracycline hydrochloride, 15-25 parts of low-substituted hydroxypropy cellulose, 5-10 parts of polyvinylpyrrolidone K30 and 1-3 parts of a sweetener. The coating contains the following ingredients (by weight): 20-30 parts of polyacrylic resin II, 2-6 parts of a plasticizer and 1-4 parts of talcum powder. According to the enteric coating aureomycin premix, polyacrylic resin II is insoluble in gastric juice but only soluble in intestinal juice such that aureomycin is effectively protected and won't be released or absorbed until reachingthe intestinal tract; the formula of the drug-loading pellets is reasonable, and the particles are small after disintegration of the low-substituted hydroxypropy cellulose, which is greatly beneficialto dissolution of the drug; and the enteric coating aureomycin premix has a good application prospect and is worthy of promotion.

Description

technical field [0001] The invention relates to an enteric-coated aureomycin premix, which belongs to the technical field of pharmaceutical excipients. Background technique [0002] The existing chlortetracycline premix is ​​dissolved in the gastric juice, so that a part of the chlortetracycline is absorbed by the stomach before reaching the intestinal tract, which greatly reduces the therapeutic effect of chlortetracycline. The bioavailability of chlortetracycline Low, not conducive to the recovery of the disease, so further research is needed. Contents of the invention [0003] In order to overcome the deficiencies in the prior art, the invention provides an enteric-coated aureomycin premix, comprising drug-loaded pellets and a coating arranged on the outside of the drug-loaded pellets, wherein the drug-loaded pellets contain There are aureomycin hydrochloride, low-substituted hydroxypropyl cellulose, povidone K30, and sweeteners. The coating contains: polyacrylic resin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/50A61K47/38A61K47/32A61K47/02A61K31/65A61P1/00
CPCA61K9/501A61K9/5026A61K31/65A61K47/32A61K47/38
Inventor 王俭
Owner 江苏昕宇药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap